Accuray Stock Price, News & Analysis (NASDAQ:ARAY)

$2.97
+0.08 (+2.77 %)
(As of 09/22/2019 04:00 PM ET)
Today's Range
$2.88
Now: $2.97
$3.06
50-Day Range
$2.56
MA: $3.05
$4.07
52-Week Range
$2.35
Now: $2.97
$5.40
Volume937,566 shs
Average Volume493,130 shs
Market Capitalization$263.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ARAY
CUSIP00439710
Phone408-716-4600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$418.79 million
Book Value$0.57 per share

Profitability

Net Income$-16,430,000.00

Miscellaneous

Employees998
Market Cap$263.68 million
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.


Accuray (NASDAQ:ARAY) Frequently Asked Questions

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its quarterly earnings data on Thursday, August, 15th. The medical equipment provider reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.05. The medical equipment provider had revenue of $117.42 million for the quarter, compared to analysts' expectations of $116.09 million. Accuray had a negative return on equity of 26.69% and a negative net margin of 3.92%. During the same period last year, the business earned ($0.01) earnings per share. View Accuray's Earnings History.

When is Accuray's next earnings date?

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Accuray.

What guidance has Accuray issued on next quarter's earnings?

Accuray issued an update on its FY 2020 earnings guidance on Thursday, August, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $410-420 million, compared to the consensus revenue estimate of $436.86 million.

What price target have analysts set for ARAY?

3 equities research analysts have issued 1-year price targets for Accuray's shares. Their predictions range from $3.90 to $4.00. On average, they anticipate Accuray's stock price to reach $3.95 in the next year. This suggests a possible upside of 33.0% from the stock's current price. View Analyst Price Targets for Accuray.

What is the consensus analysts' recommendation for Accuray?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.

Has Accuray been receiving favorable news coverage?

News articles about ARAY stock have trended somewhat negative on Sunday, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accuray earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Accuray.

Who are some of Accuray's key competitors?

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include NVIDIA (NVDA), Activision Blizzard (ATVI), Intel (INTC), Advanced Micro Devices (AMD), Tesla (TSLA), Exelixis (EXEL), Intuitive Surgical (ISRG), AVEO Pharmaceuticals (AVEO), Cypress Semiconductor (CY) and Depomed (DEPO).

Who are Accuray's key executives?

Accuray's management team includes the folowing people:
  • Mr. Joshua H. Levine, Pres, CEO & Director (Age 61)
  • Mr. Andrew Kirkpatrick, Sr. VP & COO (Age 56)
  • Mr. Lionel Hadjadjeba, Sr. VP & Chief Customer Experience Officer (Age 60)
  • Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 46)
  • Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer

Who are Accuray's major shareholders?

Accuray's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.33%), Renaissance Technologies LLC (5.79%), Primecap Management Co. CA (5.34%), Vanguard Group Inc. (4.80%), Heartland Advisors Inc. (3.94%) and D. E. Shaw & Co. Inc. (3.13%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Kelly Londy, Kevin Waters, Patrick Spine and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.

Which major investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., JPMorgan Chase & Co., BlackRock Inc., Renaissance Technologies LLC, Marshall Wace LLP, AQR Capital Management LLC, Algert Global LLC and Wells Fargo & Company MN. Company insiders that have sold Accuray company stock in the last year include Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Patrick Spine and Shigeyuki Hamamatsu. View Insider Buying and Selling for Accuray.

Which major investors are buying Accuray stock?

ARAY stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., Boston Partners, Wedge Capital Management L L P NC, Crestline Management LP, SG Americas Securities LLC and Paloma Partners Management Co. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters and Joshua Levine. View Insider Buying and Selling for Accuray.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $2.97.

How big of a company is Accuray?

Accuray has a market capitalization of $263.68 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.View Additional Information About Accuray.

What is Accuray's official website?

The official website for Accuray is http://www.accuray.com/.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]


MarketBeat Community Rating for Accuray (NASDAQ ARAY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  570
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel